Vasoactive Peptides in Portal Pressure

This study is currently recruiting participants.

Verified by Bayside Health, September 2005

First Received: September 13, 2005 Last Updated: July 25, 2007 History of Changes

Sponsored by:	Bayside Health
Information provided by:	Bayside Health
ClinicalTrials.gov Identifier:	NCT00163982

Purpose

This study is looking at the detection of vasoactive peptides in portal hypertension.

Condition	Intervention
Portal Hypertension	Drug: Norfloxacin

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Norfloxacin

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

HVPG >= 12 mmHg

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163982

Contacts

Contact: William W Kemp, MBBS, FRACP

92762000 ext 3327

w.kemp@alfred.org.au

Locations

Australia, Victoria
Alfred Hospital	Recruiting
Melbourne, Victoria, Australia, 3181
Contact: William W Kemp, MBBS, FRACP 92762000 ext 3327 w.kemp@alfred.org.au

Sponsors and Collaborators

Bayside Health

Investigators

Principal Investigator:

William W Kemp, MBBS, FRACP

The Alfred

More Information

No publications provided

Study ID Numbers:	AH4204
Study First Received:	September 13, 2005
Last Updated:	July 25, 2007
ClinicalTrials.gov Identifier:	NCT00163982 History of Changes
Health Authority:	Australia: Human Research Ethics Committee

Keywords provided by Bayside Health:

HVPG > 12 mmHg

Study placed in the following topic categories:

Anti-Infective Agents
Anti-Bacterial Agents
Norfloxacin
Liver Diseases
Digestive System Diseases

Portal Hypertension
Vascular Diseases
Hypertension, Portal
Hypertension

Additional relevant MeSH terms:

Anti-Infective Agents
Liver Diseases
Norfloxacin
Molecular Mechanisms of Pharmacological Action
Vascular Diseases
Enzyme Inhibitors
Hypertension, Portal

Pharmacologic Actions
Anti-Bacterial Agents
Digestive System Diseases
Therapeutic Uses
Cardiovascular Diseases
Nucleic Acid Synthesis Inhibitors
Hypertension

ClinicalTrials.gov processed this record on September 11, 2009